FDA approves Lilly and Boehringer’s take on Sanofi’s top-selling insulin

Damian Garde

Partners Eli and Boehringer Ingelheim inched closer to challenging Sanofi's best-selling , winning FDA approval for their on the blockbuster Lantus as they wait for its U.S. patent protection to expire.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2019 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS